Skip to main content Accessibility help
×
×
Home

Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases

  • Paula Grammas (a1) (a2), Joseph Martinez (a1) and Bradley Miller (a1) (a2) (a3)
Abstract

Diseases of the central nervous system (CNS) pose a significant health challenge, but despite their diversity, they share many common features and mechanisms. For example, endothelial dysfunction has been implicated as a crucial event in the development of several CNS disorders, such as Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, multiple sclerosis, human immunodeficiency virus (HIV)-1-associated neurocognitive disorder and traumatic brain injury. Breakdown of the blood–brain barrier (BBB) as a result of disruption of tight junctions and transporters, leads to increased leukocyte transmigration and is an early event in the pathology of these disorders. The brain endothelium is highly reactive because it serves as both a source of, and a target for, inflammatory proteins and reactive oxygen species. BBB breakdown thus leads to neuroinflammation and oxidative stress, which are implicated in the pathogenesis of CNS disease. Furthermore, the physiology and pathophysiology of endothelial cells are closely linked to the functioning of their mitochondria, and mitochondrial dysfunction is another important mediator of disease pathology in the brain. The high concentration of mitochondria in cerebrovascular endothelial cells might account for the sensitivity of the BBB to oxidant stressors. Here, we discuss how greater understanding of the role of BBB function could lead to new therapeutic approaches for diseases of the CNS that target the dynamic properties of brain endothelial cells.

Copyright
Corresponding author
*Corresponding author: Paula Grammas, Garrison Institute on Aging, Texas Tech University Health Sciences Center, 3601 4th Street Stop 9424, Lubbock, TX 79430, USA. E-mail: paula.grammas@ttuhsc.edu
References
Hide All
1Florey, Lord. (1966) The endothelial cell. British Medical Journal 2, 487-490
2Gimbrone, M.A., Cotran, R.S. and Folkman, J. (1974) Human vascular endothelial cells in culture. Growth and DNA synthesis. Journal of Cell Biology 60, 673-684
3Nachman, R.L. and Jaffe, E.A. (2004) Endothelial cell culture: beginnings of modern vascular biology. Journal of Clinical Investigation 114, 1037-1040
4Aird, W.C. (2003) Endothelial cell heterogeneity. Critical Care Medicine 31, 5221-5230
5Chi, J.T. et al. (2003) Endothelial cell diversity revealed by global expression profiling. Proceedings of the National Academy of Sciences of the United States of America 100, 10623-10628
6Zlokovic, B.V. (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201
7Guo, S. and Lo, E.H. (2009) Dysfunctional cell–cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke 40, S4-S7
8Pardridge, W.M. (1983) Brain metabolism: a perspective from the blood–brain barrier. Physiological Reviews 63, 1481-1535
9Ribatti, D. et al. (2006) Development of the blood–brain barrier: a historical point of view. The Anatomical Record: Neuroanatomist 289B, 3-8
10Reese, T.S. and Karnovsky, M.J. (1967) Fine structural localization of a blood–brain barrier to exogenous peroxidase. Journal of Cell Biology 34, 207-217
11Hardebo, J.E. et al. (1979) Studies on the enzymatic blood–brain barrier: qualitative measurements of DOPA decarboxylase in the wall of microvessels as related to the parenchyma in various CNS regions. Acta Physiologica Scandinavica 105, 453-460
12Kalaria, R.N. and Harik, S.I. (1987) Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human. Journal of Neurochemistry 49, 856-864
13Gerhart, D.Z. (1997) Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. American Journal of Physiology (London) 273, E207-E213
14Smith, Q.R. and Stoll, J. (1998) Blood-brain barrier amino acid transport. In Introduction to the Blood–Brain Barrier (Pardridge, W.M., ed), pp. 188-197, Cambridge University Press, Cambridge, UK
15Tsuji, A. (2005) Small molecular drug transfer across the blood–brain barrier via carrier-mediated transport system. NeuroRx®: The Journal of the American Society for Experimental Therapeutics 2, 54-62
16Ohtsuki, S. and Terasaki, T. (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharmacology Research 24, 1745-1758
17Spector, R. and Johanson, C.E. (2007) Vitamin transport and homeostasis in mammalian brain: focus on Vitamins B and E. Journal of Neurochemistry 103, 425-438
18Attwell, D. et al. (2010) Glial and neuronal control of brain blood flow. Nature 468, 232-243
19Park, J.A. et al. (2003) Coordinated interaction of the vascular and nervous systems: from molecule- to cell-based approaches. Biochemical and Biophysical Research Communications 311, 247-253
20Lok, J. et al. (2007) Cell-cell signaling in the neurovascular unit. Neurochemical Research 32, 2032-2045
21Lai, C.H., Kuo, K.H. (2005) The critical component to establish in vitro BBB model: pericyte. Brain Research Reviews 50, 258-265
22Krueger, M. and Bechmann, I. (2010) CNS pericytes: concepts, misconceptions, and a way out. Glia 58, 1-10
23Iadecola, C. (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nature Reviews Neuroscience 5, 347-360
24Benarroch, E. (2007) Neurovascular unit dysfunction: a vascular component of Alzheimer's disease? Neurology 68, 1730-1732
25Zlokovic, B.V. (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends in Neuroscience 28, 202-208
26Zacchigna, S., Lambrechts, D. and Carmeliet, P. (2008) Neurovascular signaling defects in neurodegeneration. Nature Reviews Neuroscience 9, 169-181
27Schnitzer, J.E. (1998) Vascular targeting as a strategy for cancer. New England Journal of Medicine 339, 472-474
28Versari, D. et al. (2009) Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 32, S314-S321
29Tang, E.H. and Vanhoutte, P.M. (2010) Endothelial dysfunction: a strategic target in the treatment of hypertension? Pflugers Archiv: European Journal of Physiology 459, 99501004
30Gimbrone, M.A. et al. (1997) Hemodynamics, endothelial gene expression and atherogenesis. Annals of the New York Academy of Science 811, 1-10
31Barcia, C. et al. (2005) Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. Journal of Neural Transmission 112, 1237-1248
32Banks, W.A., Ercal, N. and Price, T.O. (2006) The blood–brain barrier in neuroAIDS. Current HIV Research 4, 259-266
33Morel, N. et al. (2008) Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury. Journal of Trauma 64, 698-704
34Zhong, Z. et al. (2008) ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nature Neuroscience 11, 420-422
35Altman, R. and Rutledge, J.C. (2010) The vascular contribution to Alzheimer's disease. Clinical Science (London) 119, 407-421
36Alexander, J.S. et al. (2011) Multiple sclerosis and cerebral endothelial dysfunction: mechanisms. Pathophysiology 18, 3-12
37Israel, A.K. et al. (2011) Peripheral endothelial dysfunction in patients suffering from acute schizophrenia: a potential marker for cardiovascular morbidity? Schizophrenia Research 128, 44-50
38Chironi, G.N. et al. (2009) Endothelial microparticles in diseases. Cell and Tissue Research 335, 143-151
39Boulanger, C.M. (2010) Microparticles, vascular function and hypertension. Current Opinion in Nephrology and Hypertension 19, 177-180
40Jung, K.H. et al. (2009) Circulating endothelial microparticles as a marker of cerebrovascular disease. Annals of Neurology 66, 191-199
41Minagar, A. et al. (2001) Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 56, 1319-1324
42Jy, W. et al. (2004) Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis. Frontiers in Bioscience 9, 3137-3144
43Jimenez, J. et al. (2005) Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Multiple Sclerosis 11, 310-315
44Shcherbakova, I.V. et al. (2005) Markers of endothelial dysfunction in attack-like schizophrenia. Zhurnal Nevrologii I Psikhiatri Imeni S. S. Korsakova 105, 43-46
45Ukkonen, M. et al. (2007) Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis. Multiple Sclerosis 13, 701-701
46Ewers, M., Mielke, M.M. and Hampel, H. (2010) Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Experimental Gerontology 45, 75-79
47Dzau, V.J. et al. (2005) Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension 46, 7-18
48Van Craenenbroeck, E.M. and Conraads, V.M. (2010) Endothelial progenitor cells in vascular health: focus on lifestyle. Microvascular Research 79, 184-192
49Asahara, T. et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967
50Möbius-Winkler, S. et al. (2009) Endothelial progenitor cells: implications for cardiovascular disease. Cytometry 75A, 25-37
51Umemura, T. and Higashi, Y. (2008) Endothelial progenitor cells: therapeutic target for cardiovascular diseases. Journal of Pharmacological Science 108, 1-6
52Lee, S.T. et al. (2009) Reduced circulating angiogenic cells in Alzheimer disease. Neurology 72, 1853-1863
53Wu, Z. et al. (2005) Role of MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer's disease. Nature Medicine 11, 959-965
54Oldendorf, W.H., Cornford, M.E. and Brown, W.J. (1977) The apparent work capability of the blood–brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Annals of Neurology 1, 409-417
55Förster, C. (2008) Tight junctions and the modulation of barrier function in disease. Histochemistry and Cell Biology 130, 55-70
56Arhart, R.W. (2010) A possible haemodynamic mechanism for amyotrophic lateral sclerosis. Medical Hypotheses 75, 341-346
57Weir, B. (2010) Multiple sclerosis – a vascular etiology? Canadian Journal of Neurological Science 37, 745-757
58Bennett, J. et al. (2010) Blood–brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. Journal of Immunology 229, 180-191
59Plumb, J. et al. (2002) Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathology 12, 154-169
60Kirk, J. et al. (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibers of vessel and is associated with blood–brain barrier leakage and active demyelination. Journal of Pathology 201, 319-327
61Minagar, A. and Alexander, J.S. (2003) Blood–brain barrier disruption in multiple sclerosis. Multiple Sclerosis 9, 540-549
62Holman, D.W., Klein, R.S. and Ransohoff, R.M. (2011) The blood–brain barrier, chemokines and multiple sclerosis. Biochimcia et Biophysica Acta 1812, 220-230
63Garbuzova-Davis, S. et al. (2007) Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE 2, e1205
64Engelhardt, J.I. and Appel, S.H. (1990) IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Archives of Neurology 47, 1210-1216
65Nicaise, C. et al. (2009) Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Research 1301, 152-162
66Ances, B.M. and Clifford, D.B. (2008) HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Current Neurology and Neuroscience Reports 8, 455-461
67Kanmogne, G.D. et al. (2007) HIV-1 gp120 compromises blood–brain barrier integrity and enhances monocyte migration across blood–brain barrier: implication for viral neuropathogenesis. Journal of Cerebral Blood Flow and Metabolism 27, 123-134
68Ramirez, S.H. et al. (2010) Dyad of CD40/CD40 ligand fosters neuroinflammation at the blood–brain barrier and is regulated via JNK signaling: implications for HIV-1 encephalitis. Journal of Neuroscience 30, 9454-9464
69Yang, B. et al. (2008) HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood–brain barrier: modulatory effects of STAT1 signaling. Microvascular Research 77, 212-219
70Ricardo-Dukelow, M. et al. (2007) HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. Journal of Neuroimmunology 185, 37-46
71Shen, S. and Zhang, W. (2010) ABC transporters and drug efflux at the blood–brain barrier. Reviews in Neuroscience 21, 29-53
72Ferreira, I.L. et al. (2010) Multiple defects in energy metabolism in Alzheimer's disease. Current Drug Targets 11, 1193-1206
73Chetelat, G. et al. (2003) Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 60, 1374-1377
74Gibson, G.E. and Shi, Q. (2010) A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. Journal of Alzheimer's Disease 20, S591-S607
75Kalaria, R.N. and Harik, S.I. (1989) Reduced glucose transporter at the blood–brain barrier in cerebral cortex in Alzheimer disease. Journal of Neurochemistry 53, 1083
76Pimplikar, S.W. (2009) Reassessing the amyloid cascade hypothesis of Alzheimer's disease. International Journal of Biochemistry and Cell Biology 41, 1261-1268
77Deane, R., Bell, R.D., Sagare, A., and Zlokovic, B.V. (2009) Clearance of amyloid-β peptide across the blood–brain barrier: implications for therapies in Alzheimer's disease. CNS and Neurological Disorders Drug Targets 8, 16-30
78Deane, R. et al. (2004) RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood–brain barrier. Stroke 35, 2628-2631
79Bell, R.D. et al. (2009) SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells. Nature Cell Biology 11, 143-153
80Deane, R. et al. (2003) RAGE mediates amyloid-β peptide transport across the blood–brain barrier and accumulation in brain. Nature Medicine 9, 907-913
81Yan, S.D. et al. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691
82Kumar-Singh, S. et al. (2005) Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. American Journal of Pathology 167, 527-543
83Shibata, M. et al. (2000) Clearance of Alzheimer's amyloid β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 106, 1489-1499
84Jaeger, L.B. (2009) Lipopolysaccharide alters the blood–brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain, Behavior and Immunology 23, 507-517
85Qian, L., Flood, P.M. and Hong, J.S. (2010) Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. Journal of Neural Transmission 117, 971-999
86Hawkins, R.A. et al. (2006) Structure of the blood–brain barrier and its role in the transport of amino acids. Journal of Nutrition 136, 218S-226S
87Carvey, P.M. et al. (2005) 6-Hydroxydopamine-induced alterations in blood–brain barrier permeability. European Journal of Neuroscience 22, 1158-1168
88Kortekaas, R. et al. (2005) Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Annals of Neurology 57, 176-179
89Farkas, E. et al. (2000) Pathological features of cerebral cortical capillaries are double in Alzheimer's disease and Parkinson's disease. Acta Neuropathologica (Berlin) 100, 395-402
90Ohtsuki, S. et al. (2010) Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease. Biological and Pharmaceutical Bulletin 33, 1250-1252
91Lee, C.G. et al. (2004) MDR1, the blood–brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. Journal of Medical Genetics 41, e60
92Bartels, A.L. et al. (2008) Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, SP and MSA. Journal of Neural Transmission 115, 1001-1009
93Hartz, A.M.S. et al. (2003) Rapid modulation of P-glycoprotein-mediated transport at the blood–brain barrier by tumor necrosis factor-α and lipopolysaccharide. Molecular Pharmacology 69, 462-470
94Funke, C. et al. (2009) Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. Journal of Neural Transmission 116, 443-450
95Westerlund, M. et al. (2009) Association of polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism and Related Disorders 15, 422-424
96Grammas, P. (2011) Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. Journal of Neuroinflammation 25, 8-26
97Harris, L.W. et al. (2008) The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PloS ONE 3, e3964
98Grammas, P., Moore, P. and Weigel, P.H. (1999) Microvessels from Alzheimer's disease brain kill neurons in vitro. American Journal of Pathology 154, 337-342
99Grammas, P. (2000) A damaged microcirculation contributes to neuronal cell death in Alzheimer's disease. Neurobiology of Aging 21, 199-205
100Yin, X. et al. (2010) Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. American Journal of Pathology 176, 1600-1606
101Huang, C. et al. (2008) JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. Journal of Neuroimmunology 204, 118-125
102Choi, M.S. et al. (2008) Activation of protease-activated receptor1 mediates induction of matrix metalloproteinase-9 by thrombin in rat primary astrocytes. Brain Research Bulletin 76, 368-375
103Rosenberg, G.A. (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurology 8, 205-216
104Grammas, P. and Ovase, R. (2001) Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiology of Aging 22, 837-842
105Grammas, P., Samany, P.G. and Thirumangalakudi, L. (2006) Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. Journal of Alzheimer's Disease 9, 51-58
106Bugno, M. et al. (1999) Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines. FEBS Journal 448, 9-14
107Vilalta, A. et al. (2010) Matrix metalloproteinases in neurological brain lesions: a new therapeutic target? Reviews in Neurology 51, 95-107
108Zhang, H. et al. (2010) Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. The Neuroscientist 16, 156-170
109Sternlicht, M.D. and Werb, Z. (2001) How matrix metalloproteinases regulate cell behavior. Annual Review of Cellular and Developmental Biology 17, 463-516
110Visse, R. and Nagase, H. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Circulation Research 92, 827-839
111del Zoppo, G.J. (2010) The neurovascular unit, matrix proteases, and innate inflammation. Annals of the New York Academy of Sciences 1207, 46-49
112Ries, C. and Petrides, P.E. (1995) Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biology Chemistry Hoppe-Seyler 376, 345-355
113Sokolova, E. and Reiser, G. (2008) Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thrombosis and Haemostasis 100, 576-581
114Maragoudakis, M.E., Tsopanoglou, N.E. and Andriopoulou, P. (2002) Mechanism of thrombin-induced angiogenesis. Biochemical Society Transactions 20, 173-177
115Cunningham, L.A., Wetzel, M. and Rosenberg, G.A. (2005) Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50, 329-339
116Amantea, D. et al. (2009) Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS Journal 276, 13-26
117Schönbeck, U., Mach, F. and Libby, P. (1998) Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1 independent pathway of IL-1 beta processing. Journal of Immunology 161, 3340-3346
118Woessner, J.F. and Nagase, H. (2000) Matrix Metalloproteinases and TIMPs, Oxford University Press, New York
119Sheu, B.C. et al. (2001) A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Research 61, 237-242
120Rosenberg, G.A. (2002) Matrix metalloproteinases and neuroinflammation in multiple sclerosis. The Neuroscientist 8, 586-595
121Persidsky, Y. et al. (2006) Rho-mediated regulation of tight junctions during monocyte migration across the blood–brain barrier in HIV-1 encephalitis (HIVE). Blood 107, 4770-4780
122Huang, W. et al. (2009) PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulation of matrix metalloproteinase and protease activities. FASEB Journal 23, 1596-1606
123Dhawan, S. et al. (1995) HIV-1 infection alters monocyte interactions with human microvascular endothelial cells. Journal of Immunology 154, 422-432
124Thirumangalakudi, L. et al. (2006) Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. Journal of Alzheimer's Disease 10, 111-118
125Miyakawa, T. et al. (1982) The relationship between senile plaques and cerebral blood vessels in Alzheimer's disease and senile dementia. Morphological mechanism of senile plaque production. Virchows Archives (Cellular Pathology) 40, 121-129
126Lee, E.J. et al. (2010) Alpha-synuclein activates microglia by inducing the expression of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. Journal of Immunology 185, 615-623
127Tamo, W. et al. (2002) Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels. Neuroscience Letters 326, 5-8
128Kim, S.T. et al. (2010) Matrix metalloproteinase-3 contributes to vulnerability of the nigral dopaminergic neurons. Neurochemistry International 56, 161-167
129Mizoguchi, H. et al. (2009) Matrix metalloproteinase-9 inhibition improves amyloid-β-mediated cognitive impairment and neurotoxicity in mice. Journal of Pharmacology and Experimental Therapeutics 331, 14-22
130Levin, J. et al. (2009) Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Experimental Neurology 214, 201-208
131Pimenta de Castro, I., Martins, L.M. and Tufi, R. (2010) Mitochondrial quality control and neurological disease: an emerging connection. Expert Reviews in Molecular Medicine 12, e12
132Reeve, A.K., Krishnan, K.J. and Turnbull, D. (2008) Age related mitochondrial degenerative disorders in humans. Biotechnology Journal 3, 750-756
133Müller, W.E. et al. (2010) Mitochondrial dysfunction: Common final pathway in brain aging and Alzheimer's disease-Therapeutic aspects. Molecular Neurobiology 41, 159-171
134Sakar, D. and Fisher, P.D. (2006) Molecular mechanisms of aging-associated inflammation. Cancer Letters 236, 3-23
135Tripathy, D. et al. (2010) Cerebrovascular expression of proteins related to inflammation, oxidative stress and neurotoxicity is altered with aging. Journal of Neuroinflammation 7, 63
136Victor, V.M. and Rocha, M. (2007) Targeting antioxidants to mitochondria: potential new therapeutic strategy for cardiovascular diseases. Current Pharmaceutical Design 13, 845-863
137Puddu, P. et al. (2009) The emerging role cardiovascular risk factor-induced mitochondrial dysfunction in atherogenesis. Journal of Biomedical Science 16, 112-121
138Davidson, S.M. and Duchen, M.R. (2007) Endothelial mitochondria: contributing to vascular function and disease. Circulation Research 100, 1128-1141
139Kolev, K. et al. (2003) Matrix metalloproteinase-9 expression in post-hypoxic human brain capillary endothelial cells: H2O2 as a trigger and NF-kappaB as a signal transducer. Thrombosis and Haemostasis 90, 528-537
140Pu, P.B., Lu, J. and Moochhala, S. (2009) Involvement of ROS in BBB dysfunction. Free Radical Research 43, 348-364
141Hamdheydari, L. et al. (2003) Oxidized LDLs affect nitric oxide and radical generation in brain endothelial cells. Biochemical Biophysical Research Communications 311, 486-490
142Chang, H.C. et al. (2010) Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells. Journal of Cerebral Blood Flow and Metabolism 3, 842-54
143Closhen, D. et al. (2010) CRP-induced levels of oxidative stress are higher in brain than aortic endothelial cells. Cytokine 50, 117-120
144Martin, L.J. (2010) Mitochondrial pathobiology in Parkinson's disease and amyotrophic lateral sclerosis. Journal of Alzheimer's disease 20, S335-S356
145Fernandez-Checa, J.C. et al. (2010) Oxidative stress and altered mitochondrial function in neurodegenerative diseases: lessons from mouse models. CNS Neurological Disorders and Drug Targets 9, 439-454
146Lopez, G. and Sidransky, E. (2010) Autosomal recessive mutations in the development of Parkinson's disease. Biomarkers in Medicine 4, 713-721
147Casetta, I., Govoni, V. and Granieri, E. (2005) Oxidative stress, antioxidants and neurodegenerative diseases. Current Pharmacologic Design 11, 2033-2052
148Tanner, C.M. et al. (2011) Rotenone, paraquat and Parkinson's disease. Environmental Health Perspectives January 26 [Epub ahead of print]
149dos Santos, A.P. et al. (2010) Rat brain endothelial cells are a target of manganese toxicity. Brain Research 1326, 152-161
150Aliev, G. et al. (2003) Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease. Neurotoxicity Research 5, 491-504
151Claudio, L. (1996) Ultrastructural features of the blood–brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathologica 91, 6-14
152Xu, J. et al. (2001) Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. Journal of Cerebral Blood Flow and Metabolism 21, 702-710
153Wong, P.C. et al. (1995) An adverse property of a familial ALS-SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14, 1105-1116
154Kong, J. and Xu, Z. (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. Journal of Neuroscience 18, 32410-3250
155Pedrini, S. et al. (2010) ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2. Human Molecular Genetics 19, 2974-2986
156Pardridge, W.M. (2005) The blood–brain barrier and neurotherapeutics. NeuroRx®: The Journal of the American Society for Experimental Therapeutics 2, 1-2
157Agarwal, S. et al. (2011) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Reviews in Molecular Medicine 13, e17
158Lorenzl, S. et al. (2003) Tissue inhibitors of matrix metalloproteinases in neuromuscular disease. Journal of the Neurological Sciences 207, 71-76
159Renaud, S. and Leppert, D. (2007) Matrix metalloproteinases in neuromuscular disease. Muscle and Nerve 36, 1-13
160Horstmann, S. et al. (2010) Matrix metalloproteinases in peripheral blood in cerebrospinal fluid in patients with Alzheimer's disease. International Psychogeriatrics 22, 966-972
161Sastre-Garriga, J. et al. (2004) Decreased MMP-9 production in primary progressive multiple sclerosis patients. Multiple Sclerosis 10, 376-380
Neuwelt, E. et al. (2008) Strategies to advance translational research into brain barriers. Lancet Neurology 7, 84-96
Zlokovic, B. (2010) Neurodegeneration and the neurovascular unit. Nature Medicine 16, 1370-1371
Grammas, P. et al. (2008) Neurodegeneration and the brain barriers. www.ibbsoc.org/PDFs/Neurodegeneration.pdf
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed